IP Library › Granted Patent US 11,833,190
Granted Patent B2
US 11,833,190 · App. 17/153,229 · Granted Dec 5, 2023

Serum albumin-binding fibronectin type III domains

Inventors: Michael Diem (Spring House, PA); Steven Jacobs (Spring House, PA); Karyn O'Neil (Spring House, PA); Thomas Rutkoski (Spring House, PA)
Assignee: Janssen Biotech, Inc.
A61K38/39A61K47/549C07K14/78C07K16/18C07K16/40G01N33/68A61K2039/505C07K2317/94C07K2318/20C07K2319/30C07K2319/31C07K2319/70G01N2333/765G01N2333/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,833,190
App. No.
17/153,229
Granted
Dec 5, 2023
Kind
B2
Abstract

Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Claims (11)

1. A protein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 53.

2. The protein of claim 1 , wherein the protein is at least 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 53.

3. The protein of claim 1 , wherein the protein comprises an amino acid sequence that has 1, 2, 3, or substitutions when compared to the amino acid sequence of SEQ ID NO: 53.

4. A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

5. A method of detecting the presence of human serum albumin in a biological sample comprising contacting the biological sample with the protein of claim 1 and determining the binding of the biological sample to the protein.

6. A kit comprising the protein of claim 1 .

7. A molecule comprising a first domain and a second domain, wherein the first domain comprises the protein of claim 1 and the second domain is a molecule that binds to a target protein other than human serum albumin.

8. The protein of claim 1 , wherein the protein is at least 97% identical to the amino acid sequence of SEQ ID NO: 53.

9. The protein of claim 1 , wherein the protein is at least 98% identical to the amino acid sequence of SEQ ID NO: 53.

10. The protein of claim 1 , wherein the protein is at least 99% identical to the amino acid sequence of SEQ ID NO: 53.

11. A protein comprising the amino acid sequence of SEQ ID NO: 53.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2021
From: DIEM, MICHAEL; JACOBS, STEVEN; O'NEIL, KARYN; RUTKOSKI, THOMAS
To: JANSSEN BIOTECH, INC.
Reel/Frame 054968/0696 →
Continuity (3)
Continuation 15611296 · Jun 1, 2017
Provisional Application 62345190 · Jun 3, 2016
Related Publication 20210228688A1 · Jul 29, 2021
Cited By (1)
US 12,599,652